Q-omics provides the consensus-scored SHLD2P3 profile across patient tissues and cancer cell-line models. SHLD2P3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SHLD2P3 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, SHLD2P3 RNA expression shows 18,049 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, THCA, and UVM as cancer lineages where SHLD2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHLD2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHLD2P3 survival associations across molecular data types. SHLD2P3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHLD2P3 RNA expression–survival associations across cancer types. High SHLD2P3 expression shows unfavorable associations in UCEC, ACC, OV and STAD, but favorable associations in UCS and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for SHLD2P3 RNA expression.
This table summarizes SHLD2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SHLD2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHLD2P3 shows lower tumor expression in THCA, KICH, CHOL, READ, LIHC and UCEC. The THCA box plot shows higher SHLD2P3 RNA expression in normal versus tumor tissue (log2 FC = −0.287, t-test p < 0.001).
This table shows molecular features associated with SHLD2P3 in patient tissues and cancer cell lines. In patient samples, SHLD2P3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
